What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?
Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor.
Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.
A look at how the genetics-based research field can become more fully integrated in all areas of health care going forward.
Although excessive use can lead to fatigue, alerts can help proactively identify and prevent drug interactions.
At least 6 adalimumab biosimilars are set to launch in July 2023.
Navigating Ethical, Financial Considerations When Delivering Cancer Care
April 30th 2024“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.